ORM-12741

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C20H23NO3
Molecular Weight	325.4015
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC1=CC=CC(=C1)[C@H]2CCCN(C[C@H]3COC4=C(O3)C=CC=C4)C2

InChI

InChIKey=FOESNAGBEJURCI-WMZOPIPTSA-N

InChI=1S/C20H23NO3/c22-17-7-3-5-15(11-17)16-6-4-10-21(12-16)13-18-14-23-19-8-1-2-9-20(19)24-18/h1-3,5,7-9,11,16,18,22H,4,6,10,12-14H2/t16-,18-/m0/s1

HIDE SMILES / InChI

Description
Sources: http://adisinsight.springer.com/drugs/800022078https://www.ncbi.nlm.nih.gov/pubmed/29067315 | https://www.ncbi.nlm.nih.gov/pubmed/24489014 | https://adisinsight.springer.com/drugs/800029247
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/16317384 | https://www.ncbi.nlm.nih.gov/pubmed/17902637

Juvantia Pharma and Orion developed ORM-12741, also known as ORM-10921, a novel selective antagonist of alpha-2C adrenoceptors for the treatment of depression and Alzheimer's disease. ORM-12741 participated in phase II clinical trial where was evaluated the safety and efficacy of the drug in patients with Alzheimer's disease. In spite of the successfully completed phase II, further study of the drug for this disease was discontinued. In addition, ORM-12741 participated in clinical trial phase II to prove the concept that this drug could prevent blood vessel spasms for Raynaud's phenomenon. Raynaud's phenomenon is a disorder of the digital blood vessels resulting in episodic impairment of blood flow. However, this study was terminated because of the recommendation by study Data and Safety Monitoring Committee to the sponsor following the interim analysis of 8 subjects.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Estrogen receptor 72 Target ID: CHEMBL2093866 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17902637	Interacts 323
Nuclear factor NF-kappa-B complex 11 Target ID: CHEMBL2094258 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17902637	Inhibitor 8504

Conditions

Condition	Modality	Targets	Highest Phase	Product
Septic shock 21 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16317384	Primary		Preclinical	Unknown Approved Use Unknown
Rheumatoid arthritis 320 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17902637 http://adisinsight.springer.com/drugs/800022078	Primary		Phase I 438	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
The α2C-adrenoceptor antagonist, ORM-10921, exerts antidepressant-like effects in the Flinders Sensitive Line rat.	2017-02	27749317
Tolerability of ORM-12741 and effects on episodic memory in patients with Alzheimer's disease.	2017-01	29067315
Therapeutic Potential of Selectively Targeting the α2C-Adrenoceptor in Cognition, Depression, and Schizophrenia-New Developments and Future Perspective.	2017	28855875
The α2C-adrenoceptor antagonist, ORM-10921, has antipsychotic-like effects in social isolation reared rats and bolsters the response to haloperidol.	2016-11-03	27381554
A double-blind, randomized, placebo-controlled crossover trial of the α2C-adrenoceptor antagonist ORM-12741 for prevention of cold-induced vasospasm in patients with systemic sclerosis.	2014-05	24489014
Estrogen receptor dependent inhibitors of NF-kappaB transcriptional activation-1 synthesis and biological evaluation of substituted 2-cyanopropanoic acid derivatives: pathway selective inhibitors of NF-kappaB, a potential treatment for rheumatoid arthritis.	2007-11-01	17902637
The activity of pathway-selective estrogen receptor ligands in experimental septic shock.	2005-12	16317384

Patents

Sample Use Guides

In Vivo Use Guide

Unknown

Route of Administration: Oral

In Vitro Use Guide

Unknown

Name

Type

Language

ORM-12741

Code

English

3-[(3R)-1-[[(2S)-2,3-Dihydro-1,4-benzodioxin-2-yl]methyl]-3-piperidinyl]phenol

Preferred Name

English

DB-105

Code

English

Phenol, 3-[(3R)-1-[[(2S)-2,3-dihydro-1,4-benzodioxin-2-yl]methyl]-3-piperidinyl]-

Systematic Name

English

Code System Code Type Description

SMS_ID

100000184092